On Friday, Shares of Sientra Incn (NASDAQ:SIEN), lost -12.97% to $20.19.
Sientra, declared the pricing of its follow-on public offering of 3,000,000 shares of its common stock at a price to the public of $22.00 per share. In addition, Sientra has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock on the same terms and conditions.
Piper Jaffray and Stifel are acting as joint book-running managers for the offering. Leerink Partners and William Blair are acting as co-managers.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; and breast tissue expanders.
Shares of Commscope Holding Company Inc (NASDAQ:COMM), declined -1.57% to $31.39, during its last trading session.
CommScope Holding Company, has agreed to acquire Airvana LP, a privately-held leader in small cell solutions for wireless networks.
Airvana, headquartered in Chelmsford, Massachusetts, provides award-winning 4G LTE and 3G small cell solutions that enable people to access communications, information and entertainment in the most challenging and high-value environments—offices, public venues and homes. Since its founding in 2000, Airvana has played a key role in enabling the use of mobile devices for data access. Airvana began small cell development to complement its macro cell mobile broadband infrastructure products and recently focuses exclusively on small cells. Airvana has shipped 1.5 million small cells and supports one of the largest small cell networks in the world.
CommScope Holding Company, Inc., together with its auxiliaries, provides connectivity and infrastructure solutions for wireless, business enterprise, and residential broadband networks worldwide. The company operates through three segments: Wireless, Enterprise, and Broadband.
At the end of Friday’s trade, Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), gained 4.31% to $1.21.
CAR T-cell therapies show potential in treating acute myeloid leukemia (AML) and other medical conditions, but there’s a lot of work to do before they’re ready for commercialization. Alan Leong, senior analyst with BioWatch, updates The Life Sciences Report about the current state of CAR T-cell therapeutics and how some companies are developing bispecific antibodies.
He explains the approach of a number of the companies presently in the sector, counting RepliCel Life Sciences Inc. (TSX VENTURE: RP) (REPCF) in the hair regeneration and tendinitis space; ContraVir Pharmaceuticals Inc. (CTRV), which has a new focus on pain associated with shingles and symptoms related to hepatitis B and HIV; Sunesis Pharmaceuticals Inc. (SNSS), which is focused on oncology therapeutics; and Celator Pharmaceuticals (CPXX), which has a Phase 3 study in patients with myeloid leukemia.
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Finally, Incyte Corporation (NASDAQ:INCY), ended its last trade with -3.21% loss, and closed at $125.93.
Incyte Corporation, declared it will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
